|

Decitabine Clinical Trials

27 actively recruiting trials across 14 locations

▼ -1 trial since August 2026

Also known as: 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, 5-Aza-2'-deoxycytidine, 5-aza-2'-deoxycytydine +6 more

Pipeline

Early 1: 1Phase 1: 7Phase 2: 11Phase 3: 1Phase 1/2: 6Phase 2/3: 1

Top Sponsors

  • M.D. Anderson Cancer Center6
  • University of Washington2
  • Montefiore Medical Center2
  • Mayo Clinic2
  • H. Lee Moffitt Cancer Center and Research Institute2

Indications

  • Cancer27
  • Acute Myeloid Leukemia11
  • Recurrent Acute Myeloid Leukemia4
  • Refractory Acute Myeloid Leukemia3
  • Myelodysplastic Syndrome3

Houston, Texas6 trials

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

MD Anderson Cancer Center

Phase 2
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

University of Texas MD Anderson Cancer Center

Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 2
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

MD Anderson Cancer Center

Phase 1/2
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2

Other4 trials

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Phase 1/2
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Phase 2/3
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3

Seattle, Washington3 trials

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama2 trials

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Children's Hospital of Alabama

Phase 1
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

University of Alabama at Birmingham

Phase 1

Cleveland, Ohio2 trials

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Early 1
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

Avapritinib With Decitabine in Patients With SM-AHN

Mayo Clinic - Arizona

Phase 1

Clovis, California1 trial

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

UCSF-Fresno

Phase 2

Sacramento, California1 trial

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

University of California Davis Health (UC Davis Health)

Phase 2

Jacksonville, Florida1 trial

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Mayo Clinic in Florida

Phase 1

Tampa, Florida1 trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Moffitt Cancer Center

Phase 2

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

Iowa City, Iowa1 trial

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

University of Iowa Health Care

Phase 1

Boston, Massachusetts1 trial

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Beth Israel Deaconess Medical Center

Phase 1

Mankato, Minnesota1 trial

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic Health Systems-Mankato

Phase 2

The Bronx, New York1 trial

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Montefiore Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.